Status:
COMPLETED
Acupressure in Rheumatoid Arthritis
Lead Sponsor:
University of Michigan
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
25-75 years
Phase:
NA
Brief Summary
The goal of this pilot trial is to better understand if acupressure is feasible and tolerable to people with rheumatoid arthritis.
Eligibility Criteria
Inclusion
- \- Patient is being treated for Rheumatoid Arthritis (RA) at a Rheumatology Clinic at the University of Michigan or another by rheumatologist and reports being prescribed at least one of the following medications:
- Methotrexate (Trexall, Rheumatrex)
- Hydroxychloroquine (Plaquenil)
- Sulfasalazine (Azulfadine)
- Leflunomide (Arava)
- Tocilizumab (Actemra)
- Tumor necrosis factor inhibitor (TNFi), including:
- Adalimumab (Humira) Etanercept (Enbrel) Certolizumab pegol (Cimzia) Golimumab (Simponi) Infliximab (Remicade)
- Abatacept (Orencia)
- Tocilizumab (Actemra)
- Janus kinase inhibitor (JAKi), including:
- Tofacitinib (Xeljanz) Baracitinib (Olumiant) Upadacitinib (Rinvoq)
- o Rituximab (Rituxan)
Exclusion
- Visual or hearing difficulties that would preclude participation,
- Do not speak or read English
- Do not have access to smart phone with access to mobile applications
- Severe psychiatric disorders including history of substance abuse disorders,
- Individuals on high doses of opioids (over 100 oral morphine equivalents)
- Taking blood thinners, including warfarin (Coumadin), dabigatran (Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Savaysa), or betrixaban (Bevyxxa)
- Thrombocytopenia (low platelet count)
- Expecting to receive surgery within the next year for their RA
- Pregnancy or breast feeding, or anticipate pregnancy in next year,
- Actively applying for disability or compensation, or actively involved in litigation.
- Anything at the discretion of the principal investigator or study team
Key Trial Info
Start Date :
September 15 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 20 2023
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT05412121
Start Date
September 15 2022
End Date
July 20 2023
Last Update
May 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Michigan
Ann Arbor, Michigan, United States, 48109